ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  Related Studies  
Effectiveness of Family-Focused Treatment Plus Pharmacotherapy for Bipolar Disorder in Adolescents

This study is currently recruiting participants.
Information provided by National Institute of Mental Health (NIMH)

This Tabular View shows the required WHO registration data elements as marked by

Descriptive Information Fields
Brief Title  Effectiveness of Family-Focused Treatment Plus Pharmacotherapy for Bipolar Disorder in Adolescents
Official Title  Family-Focused Treatment for Bipolar Adolescents
Brief Summary

This study will evaluate the effectiveness of family-focused treatment (FFT) plus pharmacotherapy in treating adolescents with bipolar disorder.

Detailed Description

Bipolar disorder (BPD) is a serious mental illness that causes drastic shifts in a person's mood, energy, and ability to function. BPD can strike at any age, but it most commonly develops in late adolescence or early adulthood. The disorder is characterized by alternating episodes of mania and depression, often with periods of normal mood in between. Some symptoms of a manic episode include the following behaviors: increased energy, activity, and restlessness; excessively "high," overly good, euphoric mood; and extreme irritability. In contrast, a depressive episode is characterized by a lasting sad, anxious, or empty mood; feelings of hopelessness or pessimism; and decreased energy. Adolescents with BPD have high rates of disease recurrence, suicide attempts, functional impairment, and mental health service utilization, even with aggressive treatment with mood stabilizers and antipsychotic drugs. Research has suggested that FFT, a behavioral intervention consisting of psychoeducation, communication training, and problem solving training, may lead to improvements in BPD symptoms in adolescents. This study will evaluate the effectiveness of FFT plus pharmacotherapy in treating adolescents with BPD.

Participants in this 2-year, single-blind study will be randomly assigned to receive a combination of either FFT and pharmacotherapy or enhanced care (EC) and pharmacotherapy. Medications used for the pharmacotherapy portion of the study will include mood stabilizers, such as lithium or divalproex sodium, and atypical antipsychotics, such as quetiapine. Participants will also receive anti-anxiety medications, psychostimulants, or antidepressants as needed. All participants will receive pharmacotherapy for the full 2 years. Participants assigned to EC will take part in weekly brief psychoeducation sessions for 3 weeks. Participants assigned to FFT will take part in weekly treatment sessions with their families for 12 weeks, biweekly for 12 weeks, monthly for 3 months, and then trimonthly until Month 24. Both FFT and EC treatment sessions will include psychoeducation focusing on appropriate ways to manage BPD and its cycling nature. Crisis intervention sessions will also be offered to all participants on an as-needed basis for the duration of the study. Outcomes, including BPD symptoms, functioning, and service utilization, will be measured at study visits at Months 3, 6, 9, 12, 18, and 24.

Study Phase Phase III
Study Type  Interventional
Study Design  Treatment, Randomized, Single Blind (Outcomes Assessor), Active Control, Parallel Assignment, Efficacy Study
Primary Outcome Measure  Time to recovery [ Time Frame: Measured at Month 24 ]
Time to recurrence [ Time Frame: Measured at Month 24 ]
Severity of manic and depressive symptoms [ Time Frame: Measured at Month 24 ]
Secondary Outcome Measure  Functioning [ Time Frame: Measured at Month 24 ]
Quality of life [ Time Frame: Measured at Month 24 ]
Service utilization [ Time Frame: Measured at Month 24 ]
Condition  Bipolar Disorder
Intervention  Behavioral: Family-Focused Treatment Plus Pharmacotherapy
Behavioral: Enhanced Care Plus Pharmacotherapy
MEDLINE PMIDs 15571785
Links Robert Sutherland Center for the Evaluation and Treatment of Bipolar Disorder, University of Colorado, Boulder This link exits the ClinicalTrials.gov site
Recruitment Information Fields
Recruitment Status  Recruiting
Enrollment  150
Start Date  August 2006
Completion Date April 2011
Eligibility Criteria 

Inclusion Criteria:

  • Between the ages of 13 years, 0 months and 17 years, 11 months
  • Meets DSM-IV-TR criteria for either of the following conditions: bipolar I or bipolar II disorder with a manic, mixed, or hypomanic episode within 3 months of study entry; or a depressed episode within 3 months of study entry with a prior history of a manic, hypomanic, or mixed episode (if the participant only meets criteria for a current hypomanic episode, there must also be a history of at least one prior depressive, manic, or mixed episode)
  • Has experienced severe depression, hypomania, or mania symptoms for a period of at least 1 week within the 3 months prior to study entry
  • Lives with at least one biological or step-parent who is available and willing to participate in treatment (parents not currently living with the adolescent participant may also participate)

Exclusion Criteria:

  • Currently in full recovery (experienced minimal symptoms for at least 8 continuous weeks)
  • Meets DSM-IV criteria for substance abuse disorder or substance dependence disorder within 3 months of study entry (based on the Kiddie Schedule for Affective Disorders and Schizophrenia - Present and Lifetime Version [KSADS-PL])
  • Meets current criteria for bipolar, not otherwise specified, or substance-induced mood disorder
  • Diagnosis of mental retardation (as defined by an IQ less than 70), autism, or organic central nervous system disorder
  • Severe, unremitting psychosis that is unresponsive to neuroleptic medications, and has lasted more than 3 months
  • Requires extended inpatient treatment (although participant can be hospitalized at the time of intake into the study)
  • Current life-threatening eating disorder, neurological condition, or other medical problem that requires immediate treatment
  • Exhibits or expresses serious homicidal tendencies
  • Victim of current sexual or physical abuse by parents or is in an environment marked by domestic violence among the parents or step-parents
Gender Both
Ages 13 Years to 17 Years
Accepts Healthy Volunteers No
Contacts ††
Contact: David J. Miklowitz, PhD     303-492-8575     miklow@psych.colorado.edu    
Contact: Elizabeth L. George, PhD     303-207-1161     egeorge@colorado.edu    
Location Countries  United States
Administrative Information Fields
NCT ID  NCT00332098
Organization ID R01 MH73871
Secondary IDs †† R01 MH73817, R01 MH74033, DSIR 84-CTS
Study Sponsor  National Institute of Mental Health (NIMH)
Collaborators ††
Investigators 
Principal Investigator:     David J. Miklowitz, PhD     University of Colorado at Boulder    
Principal Investigator:     Robert A. Kowatch, MD     University of Cincinnati    
Principal Investigator:     David A. Axelson, MD     University of Pittsburgh    
Information Provided By National Institute of Mental Health (NIMH)
Verification Date November 2007
First Received Date  May 30, 2006
Last Updated Date November 21, 2007

 †    Required WHO trial registration data element.
††   WHO trial registration data element that is required only if it exists.




Links to all studies - primarily for crawlers